Skip to content

A prospective,multicenter rasagiline pharmacogenomics study on Parkinson's disease

A prospective,multicenter rasagiline pharmacogenomics study on Parkinson's disease

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105342
Enrollment
Unknown
Registered
2025-07-02
Start date
2025-04-09
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Sponsors

Second Affiliated Hospital,School of Medicine,Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the 2015 International Movement Disorder Association Diagnostic Criteria for Primary Parkinson's Disease; 2. Aged between 30~75 years old; 3. No anti-Parkinson's disease-related drug therapy or stable dose of other types of drug therapy (such as levodopa, dopamine receptor agonists, etc.) within 3 months at the time of initial enrollment; 4. Have lived in the local area for at least 5 years and have a fixed residence; 5. Have not participated in other research projects at present; 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who are judged by the investigator to be allergic to the treatment of Parkinson's disease; 2. Pregnant or lactating women; 3. Severe cardiovascular and cerebrovascular diseases or abnormal liver and kidney function, such as cancer, coronary heart disease, myocardial infarction and stroke; 4. Suffering from infectious diseases such as tuberculosis and AIDS or active systemic inflammatory diseases, such as tuberculosis, rheumatoid arthritis, etc.; 5. Patients with severe other neurodegenerative diseases or secondary PD syndrome or atypical PD syndrome; 6. Those who cannot cooperate with the completion of follow-up; 7. Other circumstances that the researcher deems inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
MDS-UPDRS ? (MDS Unified-Parkinson Disease Rating Scale) score difference;

Secondary

MeasureTime frame
Changes in the non-motor symptoms; Drug side effect ;Adverse event ;

Countries

China

Contacts

Public ContactZhang Baorong

Second Affiliated Hospital,School of Medicine, Zhejiang University

brzhang@zju.edu.cn+86 139 5816 7260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026